A Phase II Clinical Trial of Weekly Paclitaxel and Carboplatin in Combination With Panitumumab in Metastatic Breast Cancer Patients With Triple Negative Disease.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Panitumumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 06 Jul 2018 Biomarkers information updated
- 02 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 17 Apr 2012 Planned end date changed from 1 Jun 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov.